Here’s Why BioTechne (TECH) Traded Lower in Q3

5 days ago 3

Soumya Eswaran

Thu, December 11, 2025 astatine 8:36 AM CST 3 min read

Mairs & Power, an concern advisor, released the third-quarter 2025 capitalist missive for the “Mairs & Power Balanced Fund.” A transcript of the missive tin beryllium downloaded here. As we determination into 2025, the market’s attraction persists, with a fewer ascendant mega-cap stocks tied to artificial quality (AI) driving astir of the favorable outcomes. The money returned 6.47% successful the archetypal 9 months of 2025. The money underperformed the benchmark composite indexes (60% S&P 500 Total Return Index and 40% Bloomberg U.S. Government/Credit Bond Index), which were up 11.35% and the Morningstar Moderate Allocation adjacent group, which roseate 10.73%. In addition, delight cheque the fund’s apical 5 holdings to cognize its champion picks successful 2025.

In its third-quarter 2025 capitalist letter, Mairs & Power Balanced Fund highlighted stocks specified arsenic Bio-Techne Corporation (NASDAQ:TECH). Bio-Techne Corporation (NASDAQ:TECH), with a marketplace capitalization of $9.478 billion, develops, manufactures, and sells beingness subject reagents, instruments, and services for the probe and objective diagnostic markets. The one-month instrumentality of Bio-Techne Corporation (NASDAQ:TECH) was 0.13%, and its shares mislaid 20.67% of their worth implicit the past 52 weeks. On December 10, 2025, Bio-Techne Corporation (NASDAQ:TECH) banal closed astatine $60.83 per share.

Mairs & Power Balanced Fund stated the pursuing regarding Bio-Techne Corporation (NASDAQ:TECH) successful its 3rd 4th 2025 capitalist letter:

"The Fund’s overweight to Health Care, combined with its vulnerability to circumstantial names successful the sector, negatively impacted comparative show during the archetypal 9 months of 2025. Bio-Techne Corporation (NASDAQ:TECH), which makes precocious prime ingredients for biopharmaceutical probe and production, underperformed owed to uncertainty astir the backing situation for biopharmaceuticals and biotech probe fixed caller national backing cuts and a anemic task superior backing environment. We person taken vantage of the caller weakness to adhd to our Bio-Techne holdings."

Bio-Techne Corporation (NASDAQ:TECH) is not connected our database of 30 Most Popular Stocks Among Hedge Funds. As per our database, 43 hedge money portfolios held Bio-Techne Corporation (NASDAQ:TECH) astatine the extremity of the 3rd quarter, which was 37 successful the erstwhile quarter. In the fiscal archetypal 4th of 2026, Bio-Techne Corporation (NASDAQ:TECH) generated $286.6 million, in revenues, down 1% year-over-year some connected integrated ground and reported basis. While we admit the imaginable of Bio-Techne Corporation (NASDAQ:TECH) arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.